CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Settings

Access type: UnknownAuthor: search.filters.author.Cecilia Perret

Search Results

Now showing 1 - 10 of 11
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Yellow fever in South America – A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN
    (Elsevier BV, 2025-09)
    Alfonso J. Rodriguez-Morales
    ;
    Abdulaziz H. Alhazmi
    ;
    Abraham Katime
    ;
    Ahneez Abdul Hameed
    ;
    Alejandra Morales
      2Scopus© Citations 13
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Intestinal protozoa in returning travellers: a GeoSentinel analysis from 2007 to 2019
    (2024)
    WEITZEL, THOMAS  
    ;
    Ashley Brown
    ;
    Michael Libman  
    ;
    Cecilia Perret
    ;
    Ralph Huits
    <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Prolonged diarrhoea is common amongst returning travellers and is often caused by intestinal protozoa. However, the epidemiology of travel-associated illness caused by protozoal pathogens is not well described.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We analysed records of returning international travellers with illness caused by Giardia duodenalis, Cryptosporidium spp., Cyclospora cayetanensis or Cystoisospora belli, reported to the GeoSentinel Network during January 2007–December 2019. We excluded records of travellers migrating, with an unascertainable exposure country, or from GeoSentinel sites that were not located in high-income countries.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>There were 2517 cases, 82.3% giardiasis (n = 2072), 11.4% cryptosporidiosis (n = 287), 6.0% cyclosporiasis (n = 150) and 0.3% cystoisosporiasis (n = 8). Overall, most travellers were tourists (64.4%) on long trips (median durations: 18–30 days). Cryptosporidiosis more frequently affected people &amp;lt; 18 years (13.9%) and cyclosporiasis affected people ≥ 40 years (59.4%). Giardiasis was most frequently acquired in South Central Asia (45.8%) and sub-Saharan Africa (22.6%), cryptosporidiosis in sub-Saharan Africa (24.7%) and South-Central Asia (19.5%), cyclosporiasis in South East Asia (31.3%) and Central America (27.3%), and cystoisosporiasis in sub-Saharan Africa (62.5%). Cyclosporiasis cases were reported from countries of uncertain endemicity (e.g. Cambodia) or in countries with no previous evidence of this parasite (e.g. French Guiana). The time from symptom onset to presentation at a GeoSentinel site was the longest amongst travellers with giardiasis (median: 30 days). Over 14% of travellers with cryptosporidiosis were hospitalized.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This analysis provides new insights into the epidemiology and clinical significance of four intestinal protozoa that can cause morbidity in international travellers. These data might help optimize pretravel advice and post-travel management of patients with travel-associated prolonged gastrointestinal illnesses. This analysis reinforces the importance of international travel-related surveillance to identify sentinel cases and areas where protozoal infections might be undetected or underreported.</jats:p> </jats:sec>
      1Scopus© Citations 14
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Brotes de salmonelosis y el tamaño y rol del Estado en Chile
    (2012)
    Alberto Fica
    ;
    Gerardo Acosta
    ;
    Jeannette Dabanch
    ;
    Cecilia Perret
    ;
    Marisa Torres
    Scopus© Citations 12  1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile
    (2023)
    Nicole Le Corre
    ;
    Katia Abarca
    ;
    Patricio Astudillo
    ;
    Marcela Potin
    ;
    Sofía López
    <jats:p>During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.</jats:p>
    Scopus© Citations 3  3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
    (2022)
    Jorge A. Soto
    ;
    Felipe Melo-González
    ;
    Cristián Gutierrez-Vera
    ;
    Bárbara M. Schultz
    ;
    Roslye V. Berríos-Rojas
    <jats:p>This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population.</jats:p>
      1Scopus© Citations 20  16
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      3Scopus© Citations 1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Cluster of Imported Vivax Malaria in Travelers Returning From Peru
    (2015)
    Thomas Weitzel  
    ;
    Jaime Labarca
    ;
    Claudia P. Cortes
    ;
    Reinaldo Rosas
    ;
    M. Elvira Balcells
      4Scopus© Citations 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      4Scopus© Citations 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      6Scopus© Citations 8
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Chikungunya, enfermedad emergente en América Latina. Descripción de los primeros casos en Chile
    (2018)
    Cecilia Perret
    ;
    Cecilia Vizcaya
    ;
    WEITZEL, THOMAS  
    ;
    Reinaldo Rosas
    ;
    Jeannette Dabanch
    Scopus© Citations 6  2